Kimball Electronics, Inc. (KE) Q2 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed picture: strong growth in the medical segment and improved gross margins are positive, but overall net sales declined, and automotive sales are down. The shareholder return plan is positive, but the Q&A reveals uncertainties about the new facility's impact on margins and revenue. The market reaction is likely to be neutral, with offsetting positive and negative factors balancing each other out.
Key Financial Performance
Net Sales $341 million, a 5% decline compared to Q2 last year. The decline was due to strong results in Medical being offset by declines in North American automotive and industrial sectors, and continued softness in China.
Medical Sales $96 million, up 15% compared to the same period last year. Growth was driven by increases in Poland and Thailand, while North America remained flat.
Automotive Sales $162 million, down 13% compared to the second quarter of last year. The decline was driven by lower sales in North America due to the electronic braking program transfer and tariff pressures, partially offset by growth in Poland and Romania.
Industrial Sales $83 million, a 5% decrease compared to Q2 last year. The decline was primarily in North America due to lower demand for HVAC systems, partially offset by higher sales in Europe from a rebound in the smart meter business.
Gross Margin Rate 8.2%, a 160 basis point improvement compared to 6.6% in the same period of fiscal 2025. The improvement was due to favorable mix, closure of the Tampa facility, favorable FX rates, and global restructuring efforts.
Adjusted Operating Income $15.3 million or 4.5% of net sales, compared to $13.3 million or 3.7% of net sales last year. The improvement was driven by higher sales and strategic investments in business transformation and IT solutions.
Adjusted Net Income $6.9 million or $0.28 per diluted share, compared to $7.4 million or $0.29 per diluted share last year. The slight decline was due to higher expenses related to strategic investments and the opening of the new Indianapolis facility.
Cash and Cash Equivalents $77.9 million as of December 31, 2025. Cash generated by operating activities was $6.9 million, marking the eighth consecutive quarter of positive cash flow.
Inventory $281.7 million, marginally higher than Q1 but down $24.5 million or 8% from a year ago.
Borrowings $154 million, up $16 million from Q1 but down $51 million or roughly 25% from a year ago.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New Medical Manufacturing Facility: Opened a state-of-the-art facility in Indianapolis for manufacturing medical products, single-use surgical instruments, and drug delivery devices like auto-injectors.
Medical Vertical Growth: Sales in the Medical vertical grew by 15% year-over-year, driven by growth in Poland and Thailand, with North America remaining flat.
Automotive Vertical Decline: Sales in the Automotive vertical declined by 13% year-over-year, primarily due to lower sales in North America and China, offset by growth in Poland and Romania.
Industrial Vertical Decline: Sales in the Industrial vertical decreased by 5% year-over-year, with declines in North America partially offset by growth in Europe.
Cash Flow: Achieved positive cash flow for the eighth consecutive quarter, generating $6.9 million in Q2.
Gross Margin Improvement: Gross margin improved to 8.2%, up 160 basis points year-over-year, driven by favorable mix, facility closure, FX rates, and restructuring efforts.
Inventory Management: Inventory decreased by 8% year-over-year, ending at $281.7 million.
Rebranding to Kimball Solutions: Announced a rebranding initiative to reflect expanded capabilities beyond traditional electronics manufacturing services, with a phased rollout starting in July 2026.
Acquisition Strategy: Actively pursuing acquisitions to bring new customers, expand geographic reach, and add manufacturing capabilities, including vertical integration.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Decline in Net Sales: Net sales for the company declined by 5% compared to Q2 last year, driven by lower sales in North American automotive and industrial sectors, as well as continued softness in China.
Automotive Sector Challenges: Sales in the automotive sector decreased by 13% year-over-year, primarily due to the electronic braking program transfer out of Reynosa in mid fiscal '25 and recent tariff pressures in the U.S. Additionally, automotive sales in China also declined.
Industrial Sector Weakness: Sales in the industrial sector fell by 5% year-over-year, with the majority of the decline occurring in North America due to reduced demand for HVAC systems.
Restructuring Costs and Strategic Investments: The company is incurring higher expenses related to restructuring efforts, strategic investments in business transformation, IT solutions, and business development, which could impact profitability in the short term.
Higher Tax Rate: The effective tax rate for Q2 was significantly higher at 47.9% compared to 1.2% last year, driven by a provision to tax return adjustment and valuation allowance adjustment associated with the expected sale of the Tampa facility.
Tariff Impacts and Economic Concerns: The company is monitoring the impact of tariffs, changes in U.S. tax subsidies, and broader economic concerns, particularly in the North American automotive and industrial verticals, which could affect future performance.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance for Fiscal 2026: Net sales are expected to be in the range of $1.4 billion to $1.46 billion, an increase from the previous guidance of $1.35 billion to $1.45 billion. This improvement is driven by strength in the Medical vertical and the ramp-up of Automotive programs at European facilities.
Adjusted Operating Income Guidance for Fiscal 2026: Adjusted operating income is now estimated to be 4.2% to 4.5% of net sales, up from the prior estimate of 4.0% to 4.25%. The improvement is attributed to higher sales, balanced against investments in the Indianapolis CMO facility, business development, and IT solutions.
Capital Expenditures Guidance for Fiscal 2026: Capital expenditures are expected to remain in the range of $50 million to $60 million for the fiscal year.
Medical Vertical Growth Expectations: The Medical vertical is expected to experience top-line growth outpacing other verticals, driven by megatrends such as an aging population, increased healthcare access, and demand for smaller, precision medical devices. The new Indianapolis facility will add capacity for manufacturing medical products.
Automotive Vertical Outlook: Growth in the Automotive vertical is expected from European facilities, particularly in steering and braking programs. However, challenges in North America due to tariffs and program transfers are being monitored.
Industrial Vertical Outlook: The Industrial vertical faces challenges in North America, particularly in the HVAC submarket, but is seeing a rebound in Europe, driven by smart meter business recovery.
Future Strategic Investments: The company plans to continue restructuring efforts in FY '26 and beyond to align cost structures with market demand. Investments in business transformation, IT solutions, and business development are ongoing to enhance capabilities.
Market Trends and FY 2027 Outlook: The company is monitoring FY '27 outlook, particularly in North American automotive and industrial verticals, in response to tariff impacts, U.S. tax subsidy changes, and economic concerns.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase Program: We invested $4.3 million in Q2 to repurchase 149,000 shares. Since October 2015, under our Board authorized share repurchase program, a total of $109.5 million has been returned to our shareowners by purchasing 6.8 million shares of common stock. We have $10.5 million remaining on the repurchase program.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What percentage of revenue did Nexteer contribute in December?
A:20%.
Q:Are other customers besides Nexteer contributing to the growth in steering and braking?
A:Yes, other customers like ZF and HL Mondo are also contributing to the growth in steering and braking.
Q:What is the capacity and growth potential of the new Indianapolis facility?
A:The facility is 300,000 square feet under roof, significantly larger than the current footprint, with considerable growth potential. However, specific revenue projections depend on the volume and type of work.
Q:Is the Indianapolis facility focused on emerging medical customers?
A:Yes, the facility is focused on emerging medical customers, with growth evenly distributed across North America, Europe, and Asia, and not driven by respiratory care.
Q:What are the value-added CMO applications expected in the Indianapolis facility?
A:The facility will focus on single-use surgical instruments, drug delivery devices like auto-injectors, and plastic injection molding.
Q:What is the outlook for Automotive growth in Q3 and Q4?
A:Automotive is expected to be flat or slightly up in Q3 due to the end of the EV100 program and new programs in Europe, which is rebounding.
Q:What are the win rates and opportunities in the portfolio?
A:Win rates are consistent, with opportunities in lift-and-shift programs and larger CMO discussions, particularly in Medical and Industrial sectors.
Q:How will the new facility impact margins?
A:In the near term, the facility will drag margins due to depreciation and operational costs, but it is expected to be accretive in the long term.
Q:What is the outlook for cash cycle days?
A:Cash cycle days are expected to decrease in Q3 from the elevated levels in Q2, with a continued focus on working capital and inventory reductions.
Q:What is the potential of the EPP and second steering design programs in Automotive?
A:The EPP program is about 2/3 the size of the old braking program and represents a strategic focus on higher-level assembly. The second steering design and ADAS are also strategic growth areas.
Q:What are the focus areas for acquisitions in the Medical space?
A:Focus areas include in vitro diagnostics and cardiology, with an emphasis on expanding customer relationships and manufacturing capabilities.
Q:Review of Unclear Management Responses
A:Management avoided providing specific revenue projections for the new Indianapolis facility, citing dependency on the volume and type of work. Additionally, while discussing the impact of the new facility on margins, the response was somewhat vague about the timeline for achieving accretive margins.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CMO facility
Cash
China
Development Treasurer
FY
Kimball Electronics
Medical vertical
Poland
Relations Strategic
Sales
Strategic Development
Tampa facility
Thailand
adjustment
day
decrease sale
development
example
expense
facility Indianapolis
improvement
income sale
investment
life
majority
manufacturing
need
plant
product
program
sale North
sale decline
share
steering braking
steering system
tax
transformation solution
wire
KE Transcript
Kimball Electronics, Inc. (KE) Q2 2026 Earnings Call Transcript
Unknown2-5
The earnings call presents a mixed picture: strong growth in the medical segment and improved gross margins are positive, but overall net sales declined, and automotive sales are down. The shareholder return plan is positive, but the Q&A reveals uncertainties about the new facility's impact on margins and revenue. The market reaction is likely to be neutral, with offsetting positive and negative factors balancing each other out.
Kimball Electronics, Inc. (KE) Q1 2026 Earnings Call Transcript
Unknown11-6
The earnings call highlights a mix of positive and negative factors. Strong adjusted income and net income, debt reduction, and cash flow are positives. However, the guidance for fiscal 2026 indicates revenue decline and modest growth in key segments. The Q&A reveals positive sentiment towards medical growth and strategic acquisitions, but concerns in the automotive sector and potential SG&A increase. Overall, the outlook is mixed with stable margins and strategic growth plans, leading to a neutral sentiment.
Kimball Electronics, Inc. (KE) Q4 2025 Earnings Conference Call Transcript
Positive8-14
The earnings call highlights a robust strategy with new facility expansion, strong focus on the medical segment, and margin improvement efforts. The Q&A reveals positive sentiment towards automation and growth initiatives, despite some vague responses on industrial plans. The reiteration of fiscal guidance, coupled with strategic investments in sales and business development, supports a positive outlook. The absence of negative financial surprises and the focus on high-growth segments suggest a positive stock price movement in the short term.
Kimball Electronics, Inc. (KE) Q3 2025 Earnings Call Transcript
Unknown5-7
The earnings call reveals several concerning financial metrics, including declining net sales, gross margins, and adjusted net income. While there are positive developments like the new Indianapolis facility and reduced borrowings, the overall sentiment is negative due to weak financial performance and conservative guidance. The Q&A session highlighted management's reluctance to provide detailed guidance and clarity on certain issues, which adds uncertainty. Despite some optimism in the Medical CMO space, the decline in other sectors and lack of strong positive catalysts lead to a negative outlook.
KE Slides
KE Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
